Payment overview · 2025
General Payments
$16,768.14
35 reported records · 7 companies
Healthcare provider profile · identity verified
Shachar Tauber, MD
Allopathic & Osteopathic Physicians|Ophthalmology · SPRINGFIELD, MO · NPI 1174689723
Verified facts
What the public records show
CMS Open Payments records show Shachar Tauber, MD received $16,768.14 in general payments during 2025 across 35 reported records.
Glaukos Corporation accounted for 75.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Miebo, Vevye, Xiidra.
Bausch & Lomb Americas Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOTEMAX as an associated drug or biological on 10 records involving 10 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Lotemax by this doctor in 2024.
Bausch & Lomb Americas Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOTEMAX SM as an associated drug or biological on 92 records involving 67 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Lotemax Sm by this doctor in 2024.
Bausch & Lomb Americas Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MIEBO as an associated drug or biological on 34133 records involving 12967 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Miebo by this doctor in 2024.
Bausch & Lomb Americas Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIIDRA as an associated drug or biological on 28163 records involving 11019 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Xiidra by this doctor in 2024.
Harrow Eye, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VEVYE as an associated drug or biological on 14430 records involving 6429 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Vevye by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Glaukos Corporation | Unresolved — no canonical attribution shown | $12,676.05 | 75.6% | 17 | 2025 |
| Johnson & Johnson Surgical Vision, Inc. | Unresolved — no canonical attribution shown | $1,936.60 | 11.6% | 11 | 2025 |
| Apellis Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $1,632.50 | 9.7% | 1 | 2025 |
| Harrow Eye, LLC | Unresolved — no canonical attribution shown | $212.39 | 1.3% | 2 | 2025 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | Unresolved — no canonical attribution shown | $132.91 | 0.8% | 1 | 2025 |
| Bausch & Lomb Americas Inc. | Unresolved — no canonical attribution shown | $93.57 | 0.6% | 2 | 2025 |
| RxSight Inc | Unresolved — no canonical attribution shown | $84.12 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $12,582.50 | 4 |
| Food and Beverage | $2,768.49 | 29 |
| Travel and Lodging | $1,417.15 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Epioxa Normalized: epioxa |
Drug | Glaukos Corporation | $8,516.30 | 2 | 2025 |
Source payment records
|
|||||
| Travoprost Intraocular Implant - iDose Normalized: travoprost intraocular implant idose |
Drug | Glaukos Corporation | $1,654.18 | 2 | 2025 |
Source payment records
|
|||||
| Syfovre Normalized: syfovre |
Drug | Apellis Pharmaceuticals, Inc. | $1,632.50 | 1 | 2025 |
Source payment records
|
|||||
| Baerveldt Glaucoma Implant (250) Normalized: baerveldt glaucoma implant 250 |
Device | Johnson & Johnson Surgical Vision, Inc. | $1,350.00 | 1 | 2025 |
Source payment records
|
|||||
| Compact Intuitiv Normalized: compact intuitiv |
Device | Johnson & Johnson Surgical Vision, Inc. | $1,350.00 | 1 | 2025 |
Source payment records
|
|||||
| Whitestar Phaco Handpiece Normalized: whitestar phaco handpiece |
Device | Johnson & Johnson Surgical Vision, Inc. | $1,350.00 | 1 | 2025 |
Source payment records
|
|||||
| KXL System Normalized: kxl system |
Device | Glaukos Corporation | $1,200.00 | 1 | 2025 |
Source payment records
|
|||||
| KXL system (not refurbished) Normalized: kxl system not refurbished |
Device | Glaukos Corporation | $726.46 | 5 | 2025 |
Source payment records
|
|||||
| iDoseTR Normalized: idosetr |
Drug | Glaukos Corporation | $579.11 | 7 | 2025 |
Source payment records
|
|||||
| iStent infinite Normalized: istent infinite |
Device | Glaukos Corporation | $565.43 | 6 | 2025 |
Source payment records
|
|||||
| Tecnis Simplicity Normalized: tecnis simplicity |
Device | Johnson & Johnson Surgical Vision, Inc. | $289.01 | 4 | 2025 |
Source payment records
|
|||||
| VEVYE Normalized: vevye |
Drug | Harrow Eye, LLC | $212.39 | 2 | 2025 |
Source payment records
|
|||||
| Photrexa Viscous and Photrexa Normalized: photrexa viscous and photrexa |
Drug | Glaukos Corporation | $179.87 | 1 | 2025 |
Source payment records
|
|||||
| TECNIS IOL Normalized: tecnis iol |
Device | Johnson & Johnson Surgical Vision, Inc. | $168.57 | 5 | 2025 |
Source payment records
|
|||||
| Cequa Normalized: cequa |
Drug | SUN PHARMACEUTICAL INDUSTRIES INC. | $132.91 | 1 | 2025 |
Source payment records
|
|||||
| AMO PHACO NEEDLE Normalized: amo phaco needle |
Device | Johnson & Johnson Surgical Vision, Inc. | $118.40 | 1 | 2025 |
Source payment records
|
|||||
| MIEBO Normalized: miebo |
Drug | Bausch & Lomb Americas Inc. | $93.57 | 2 | 2025 |
Source payment records
|
|||||
| XIIDRA Normalized: xiidra |
Drug | Bausch & Lomb Americas Inc. | $93.57 | 2 | 2025 |
Source payment records
|
|||||
| LIGHT ADJUSTABLE LENS (LAL) Normalized: light adjustable lens lal |
Device | RxSight Inc | $84.12 | 1 | 2025 |
Source payment records
|
|||||
| RXSIGHT CONTACT LENS Normalized: rxsight contact lens |
Device | RxSight Inc | $84.12 | 1 | 2025 |
Source payment records
|
|||||
| RXSIGHT INJECTOR CARTRIDGE Normalized: rxsight injector cartridge |
Device | RxSight Inc | $84.12 | 1 | 2025 |
Source payment records
|
|||||
| RXSIGHT INJECTOR HANDPIECE Normalized: rxsight injector handpiece |
Device | RxSight Inc | $84.12 | 1 | 2025 |
Source payment records
|
|||||
| RXSIGHT LIGHT DELIVERY DEVICE (LDD) Normalized: rxsight light delivery device ldd |
Device | RxSight Inc | $84.12 | 1 | 2025 |
Source payment records
|
|||||
| VYZULTA Normalized: vyzulta |
Drug | Bausch & Lomb Americas Inc. | $41.89 | 1 | 2025 |
Source payment records
|
|||||
| CATALYS SYSTEM Normalized: catalys system |
Device | Johnson & Johnson Surgical Vision, Inc. | $33.68 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MIEBO miebo |
2025 | Miebo | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VEVYE vevye |
2025 | Vevye | 2024 | 35 | exact normalized | Medicare Part D |
| XIIDRA xiidra |
2025 | Xiidra | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Bausch & Lomb Americas Inc. Exact reporting entity; no affiliate inference |
2025 | LOTEMAX open payments reported associated product |
CMS Open Payments — General Payments 10 supporting records · 10 recipient NPIs · example record 1254762767 |
Lotemax · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Bausch & Lomb Americas Inc. Exact reporting entity; no affiliate inference |
2025 | LOTEMAX SM open payments reported associated product |
CMS Open Payments — General Payments 92 supporting records · 67 recipient NPIs · example record 1254732081 |
Lotemax Sm · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Bausch & Lomb Americas Inc. Exact reporting entity; no affiliate inference |
2025 | MIEBO open payments reported associated product |
CMS Open Payments — General Payments 34133 supporting records · 12967 recipient NPIs · example record 1254730224 |
Miebo · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Bausch & Lomb Americas Inc. Exact reporting entity; no affiliate inference |
2025 | XIIDRA open payments reported associated product |
CMS Open Payments — General Payments 28163 supporting records · 11019 recipient NPIs · example record 1254730224 |
Xiidra · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Harrow Eye, LLC Exact reporting entity; no affiliate inference |
2025 | VEVYE open payments reported associated product |
CMS Open Payments — General Payments 14430 supporting records · 6429 recipient NPIs · example record 1236209940 |
Vevye · 2024 Exact normalized brand match · 1 Part D row |
35 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Prednisolone Acetate | Prednisolone Acetate | 281 | 106 |
| Restasis | Cyclosporine | 223 | 78 |
| Loteprednol Etabonate | Loteprednol Etabonate | 115 | 39 |
| Valacyclovir | Valacyclovir Hcl | 110 | 32 |
| Fluorometholone | Fluorometholone | 76 | 31 |
| Polymyxin B Sul-Trimethoprim | Polymyxin B Sulf/Trimethoprim | 55 | 32 |
| Vancomycin Hcl | Vancomycin Hcl | 49 | 14 |
| Cyclosporine | Cyclosporine | 44 | 21 |
| Tyrvaya | Varenicline Tartrate | 44 | 12 |
| Lotemax | Loteprednol Etabonate | 35 | suppressed |
| Lotemax Sm | Loteprednol Etabonate | 35 | suppressed |
| Vevye | Cyclosporine | 35 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 33 | 16 |
| Miebo | Perfluorohexyloctane/Pf | 32 | suppressed |
| Rhopressa | Netarsudil Mesylate | 30 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 26 | 12 |
| Latanoprost | Latanoprost | 24 | 11 |
| Atropine Sulfate | Atropine Sulfate | 22 | 22 |
| Eysuvis | Loteprednol Etabonate | 18 | suppressed |
| Xiidra | Lifitegrast | 18 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 16 | 13 |
| Oxervate | Cenegermin-Bkbj | 16 | suppressed |
| Rocklatan | Netarsudil Mesylat/Latanoprost | 16 | suppressed |
| Timolol Maleate | Timolol Maleate | 16 | suppressed |
| Inveltys | Loteprednol Etabonate | 14 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 12 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 12 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 12 | 12 |
| Acyclovir | Acyclovir | 11 | suppressed |
| Difluprednate | Difluprednate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $16,768.14 · 35 records | Glaukos Corporation | AMO PHACO NEEDLE, Baerveldt Glaucoma Implant (250), CATALYS SYSTEM, Cequa, Compact Intuitiv, Epioxa, KXL System, KXL system (not refurbished), LIGHT ADJUSTABLE LENS (LAL), MIEBO, Photrexa Viscous and Photrexa, RXSIGHT CONTACT LENS, RXSIGHT INJECTOR CARTRIDGE, RXSIGHT INJECTOR HANDPIECE, RXSIGHT LIGHT DELIVERY DEVICE (LDD), Syfovre, TECNIS IOL, Tecnis Simplicity, Travoprost Intraocular Implant - iDose, VEVYE, VYZULTA, Whitestar Phaco Handpiece, XIIDRA, iDoseTR, iStent infinite | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Miebo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Bausch & Lomb Americas Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error